EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OptiNose's enterprise value is $167.08 Mil.
OptiNose's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-15.55 Mil. Therefore, OptiNose's EV-to-EBITDA for today is -10.74.
The historical rank and industry rank for OptiNose's EV-to-EBITDA or its related term are showing as below:
OPTN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.53 Med: -3.03 Max: -0.89
Current: -10.74
During the past 9 years, the highest EV-to-EBITDA of OptiNose was -0.89. The lowest was -17.53. And the median was -3.03.
OPTN's EV-to-EBITDA is ranked worse than 100% of 708
companies
in the Drug Manufacturers industry
Industry Median: 13.88
vs OPTN: -10.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), OptiNose's stock price is $0.9253.
OptiNose's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.320. Therefore, OptiNose's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
OptiNose EV-to-EBITDA Historical Data
The historical data trend for OptiNose's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptiNose's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, OptiNose's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OptiNose's EV-to-EBITDA falls into.
OptiNose EV-to-EBITDA Calculation
OptiNose's EV-to-EBITDA for today is calculated as:
OptiNose's current Enterprise Value is $167.08 Mil.
OptiNose's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptiNose (NAS:OPTN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
OptiNose's share price for today is $0.9253.
OptiNose's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of OptiNose's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OPTN has been successfully added to your 